Insulin degludec/insulin aspart - Novo Nordisk
Alternative Names: DegludecPlus; IDegAsp; Insulin aspart/insulin degludec; Insulin aspart/NN1250; Insulin Degludec/Insulin Aspart 15; NN1045; NN1250/insulin aspart; NN5401; Ryzodeg; SIAC; Soluble insulin analogue combinationLatest Information Update: 05 Nov 2023
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 03 Sep 2021 No development reported - Phase-III for Type 2 diabetes mellitus in China (SC)
- 03 Sep 2021 No development reported - Phase-III for Type 2 diabetes mellitus in Serbia (SC)
- 21 May 2021 Launched for Type 2 diabetes mellitus in Lebanon prior to May 2021 (SC) (NCT04892069)